According to Zacks, “Endologix, Inc. develops, manufactures and markets products for the treatment of coronary and vascular diseases. A leader in the emerging field of vascular brachytherapy, Endologix, has developed a unique method for the delivery of radiation to prevent restenosis following the interventional treatment of atherosclerosis. “
Several other research analysts also recently commented on the company. Oppenheimer Holdings Inc. restated an outperform rating and issued a $15.00 target price on shares of Endologix in a research note on Tuesday, September 27th. Leerink Swann set a $13.00 price target on Endologix and gave the company a hold rating in a research report on Saturday, September 17th. BMO Capital Markets reiterated a buy rating and set a $15.00 price target on shares of Endologix in a research report on Wednesday, August 3rd. BTIG Research reiterated a buy rating and set a $16.00 price target on shares of Endologix in a research report on Wednesday, August 3rd. Finally, Piper Jaffray Cos. reiterated an overweight rating and set a $15.00 price target on shares of Endologix in a research report on Wednesday, August 3rd. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and nine have assigned a buy rating to the company. Endologix has an average rating of Buy and a consensus target price of $13.79.
Endologix (NASDAQ:ELGX) traded down 1.60% during trading on Tuesday, reaching $12.91. 72,900 shares of the company’s stock were exchanged. Endologix has a 12 month low of $6.51 and a 12 month high of $14.50. The firm’s market cap is $1.06 billion. The firm’s 50-day moving average price is $12.46 and its 200-day moving average price is $11.95.
Endologix (NASDAQ:ELGX) last issued its earnings results on Tuesday, August 2nd. The company reported ($0.13) EPS for the quarter, topping the consensus estimate of ($0.20) by $0.07. Endologix had a negative return on equity of 41.88% and a negative net margin of 82.39%. The business earned $51 million during the quarter, compared to the consensus estimate of $46.30 million. During the same quarter last year, the company earned ($0.18) EPS. The firm’s revenue was up 29.1% compared to the same quarter last year. On average, equities research analysts anticipate that Endologix will post ($0.74) EPS for the current year.
In related news, insider Michael V. Chobotov sold 14,000 shares of the firm’s stock in a transaction dated Friday, August 5th. The stock was sold at an average price of $12.40, for a total transaction of $173,600.00. Following the transaction, the insider now directly owns 189,269 shares of the company’s stock, valued at approximately $2,346,935.60. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, VP Jose A. Lima sold 4,710 shares of the firm’s stock in a transaction dated Friday, August 19th. The shares were sold at an average price of $11.68, for a total value of $55,012.80. Following the transaction, the vice president now directly owns 42,594 shares in the company, valued at $497,497.92. The disclosure for this sale can be found here. Corporate insiders own 3.90% of the company’s stock.
Several institutional investors have recently made changes to their positions in ELGX. Legal & General Group Plc boosted its position in shares of Endologix by 34.9% in the first quarter. Legal & General Group Plc now owns 12,570 shares of the company’s stock worth $106,000 after buying an additional 3,252 shares in the last quarter. Nomura Holdings Inc. bought a new position in shares of Endologix during the second quarter worth approximately $128,000. OLD National Bancorp IN bought a new position in shares of Endologix during the second quarter worth approximately $129,000. Teacher Retirement System of Texas boosted its position in shares of Endologix by 15.8% in the second quarter. Teacher Retirement System of Texas now owns 10,333 shares of the company’s stock worth $129,000 after buying an additional 1,407 shares during the period. Finally, Villere ST Denis J & Co. LLC bought a new position in shares of Endologix during the second quarter worth approximately $134,000.
Endologix, Inc is engaged in developing, manufacturing, marketing and selling medical devices for the treatment of aortic disorders. The Company’s products are intended for the treatment of abdominal aortic aneurysms (AAA). The AAA products are built on one of two platforms, including traditional minimally invasive endovascular repair (EVAR) or endovascular sealing (EVAS), its solution for sealing the aneurysm sac while maintaining blood flow through two blood flow lumens.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Endologix Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endologix Inc. and related companies with MarketBeat.com's FREE daily email newsletter.